High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients.
Creatine kinase
Crohn's disease
Inflammatory bowel disease
Infliximab
Ulcerative colitis
Vedolizumab
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
10
03
2021
accepted:
21
06
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific effect of treatment with TNF inhibitors has not been studied in detail. CK levels were therefore compared between infliximab- and vedolizumab-treated IBD patients. In this retrospective, monocentric study, 131 IBD cases (82 with Crohn's disease (CD), 49 with ulcerative colitis) of the Basel University Hospital IBD cohort treated either with infliximab or vedolizumab were included. Serum samples for measuring CK, lactate dehydrogenase (LDH), C-reactive protein (CRP), and fecal calprotectin (FCal) levels were collected longitudinally and analyzed using mixed additive models. No significant differences in CK levels between infliximab and vedolizumab-treated patients were observed over time. Infliximab-treated males, however, showed significantly higher CK levels than females and former smokers treated with infliximab showed significantly lower CK levels than nonsmokers. No such differences were observed in vedolizumab-treated patients. LDH and CRP were not significantly different between infliximab- and vedolizumab-treated patients, while adjusted groups showed substantially higher LDH levels with increasing age and significantly lower LDH levels in patients with longer disease duration. Infliximab patients with CD showed significantly lower CRP. However, significantly higher FCal concentrations were noted in infliximab patients independent of diagnosis, gender, disease duration, smoking behavior, and age. In our cohort, high serum CK levels are not an infliximab- or vedolizumab-specific effect.
Sections du résumé
BACKGROUND
BACKGROUND
TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific effect of treatment with TNF inhibitors has not been studied in detail. CK levels were therefore compared between infliximab- and vedolizumab-treated IBD patients.
METHODS
METHODS
In this retrospective, monocentric study, 131 IBD cases (82 with Crohn's disease (CD), 49 with ulcerative colitis) of the Basel University Hospital IBD cohort treated either with infliximab or vedolizumab were included. Serum samples for measuring CK, lactate dehydrogenase (LDH), C-reactive protein (CRP), and fecal calprotectin (FCal) levels were collected longitudinally and analyzed using mixed additive models.
RESULTS
RESULTS
No significant differences in CK levels between infliximab and vedolizumab-treated patients were observed over time. Infliximab-treated males, however, showed significantly higher CK levels than females and former smokers treated with infliximab showed significantly lower CK levels than nonsmokers. No such differences were observed in vedolizumab-treated patients. LDH and CRP were not significantly different between infliximab- and vedolizumab-treated patients, while adjusted groups showed substantially higher LDH levels with increasing age and significantly lower LDH levels in patients with longer disease duration. Infliximab patients with CD showed significantly lower CRP. However, significantly higher FCal concentrations were noted in infliximab patients independent of diagnosis, gender, disease duration, smoking behavior, and age.
CONCLUSION
CONCLUSIONS
In our cohort, high serum CK levels are not an infliximab- or vedolizumab-specific effect.
Identifiants
pubmed: 34722646
doi: 10.1159/000518264
pii: iid-0006-0165
pmc: PMC8527910
doi:
Types de publication
Journal Article
Langues
eng
Pagination
165-174Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
J.H.N. has received an unrestricted research grant from Vifor and consultancy fees from AbbVie, Jannsen, MSD, Takeda, and Pfizer. P.H. has received consultancy fees from AbbVie, Jannsen, MSD, Takeda, Pfizer, Pierre Fabre, Sandoz, and Vifor.
Références
J Rheumatol. 2012 Jan;39(1):192-4
pubmed: 22210682
J Dermatolog Treat. 2004 Sep;15(5):280-94
pubmed: 15370396
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Rev Bras Reumatol Engl Ed. 2017 Nov - Dec;57(6):590-595
pubmed: 29173693
Gut. 2015 Jan;64(1):77-83
pubmed: 24763133
Allergol Int. 2018 Apr;67(2):286-288
pubmed: 28964642
J Crohns Colitis. 2020 Sep 7;14(8):1066-1073
pubmed: 32060515
Am J Med. 2009 Jan;122(1):73-8
pubmed: 19114174
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
pubmed: 19509315
Aliment Pharmacol Ther. 2010 Mar;31(5):553-60
pubmed: 20002026
N Engl J Med. 2016 Feb 18;374(7):664-9
pubmed: 26886523
Muscles Ligaments Tendons J. 2014 Feb 24;3(4):303-12
pubmed: 24596694
Gut. 2009 Apr;58(4):501-8
pubmed: 18832524
Expert Opin Drug Saf. 2015 Jun;14(6):987-97
pubmed: 25819509
Dig Liver Dis. 2003 Sep;35(9):642-7
pubmed: 14563186
World J Gastroenterol. 2016 Nov 14;22(42):9300-9313
pubmed: 27895418
Dermatol Ther. 2004;17(5):409-26
pubmed: 15379776
JAMA. 1974 Jun 10;228(11):1395-6
pubmed: 4406615
Inflamm Bowel Dis. 2018 May 18;24(6):1266-1271
pubmed: 29718260
Dig Dis. 2013;31(3-4):336-44
pubmed: 24246984
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
Leuk Res. 2010 Jun;34(6):827-9
pubmed: 19963273
Int J Dermatol. 2008 Apr;47(4):398-401
pubmed: 18377609
Clin Pharmacokinet. 2017 Nov;56(11):1287-1301
pubmed: 28523450
J Crohns Colitis. 2017 Apr 1;11(4):400-411
pubmed: 27683800
ScientificWorldJournal. 2014 Jan 29;2014:179180
pubmed: 24600322
Inflamm Bowel Dis. 2018 Oct 12;24(11):2431-2441
pubmed: 30312414
N Engl J Med. 2019 Sep 26;381(13):1215-1226
pubmed: 31553834
MAbs. 2013 Nov-Dec;5(6):842-50
pubmed: 24492340
Am J Clin Pathol. 1983 May;79(5):582-6
pubmed: 6837521